Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
Riedmeier M, Antonini SRR, Brandalise S, Costa TEJB, Daiggi CM, de Figueiredo BC, de Krijger RR, De Sá Rodrigues KE, Deal C, Del Rivero J, Engstler G, Fassnacht M, Fernandes Luiz Canali GC, Molina CAF, Gonc EN, Gültekin M, Haak HR, Guran T, Hendriks Allaird EJ, Idkowiak J, Kuhlen M, Malkin D, Meena JP, Pamporaki C, Pinto E, Puglisi S, Ribeiro RC, Thompson LDR, Yalcin B, Van Noesel M, Wiegering V. Riedmeier M, et al. Among authors: puglisi s. Eur J Endocrinol. 2024 Mar 30;190(4):G15-G24. doi: 10.1093/ejendo/lvae038. Eur J Endocrinol. 2024. PMID: 38552173
New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, Terzolo M. Puglisi S, et al. Best Pract Res Clin Endocrinol Metab. 2020 May;34(3):101415. doi: 10.1016/j.beem.2020.101415. Epub 2020 Mar 5. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 32179008 Free article. Review.
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question.
Basile V, Puglisi S, Altieri B, Canu L, Libè R, Ceccato F, Beuschlein F, Quinkler M, Calabrese A, Perotti P, Berchialla P, Dischinger U, Megerle F, Baudin E, Bourdeau I, Lacroix A, Loli P, Berruti A, Kastelan D, Haak HR, Fassnacht M, Terzolo M. Basile V, et al. Among authors: puglisi s. J Pers Med. 2021 Apr 4;11(4):269. doi: 10.3390/jpm11040269. J Pers Med. 2021. PMID: 33916613 Free PMC article.
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M, Fassnacht M, Perotti P, Libé R, Kastelan D, Lacroix A, Arlt W, Haak HR, Loli P, Decoudier B, Lasolle H, Quinkler M, Haissaguerre M, Chabre O, Caron P, Stigliano A, Giordano R, Zatelli MC, Bancos I, Fragoso MCBV, Canu L, Luconi M, Puglisi S, Basile V, Reimondo G, Kroiss M, Megerle F, Hahner S, Kimpel O, Dusek T, Nölting S, Bourdeau I, Chortis V, Ettaieb MH, Cosentini D, Grisanti S, Baudin E, Berchialla P, Bovis F, Sormani MP, Bruzzi P, Beuschlein F, Bertherat J, Berruti A. Terzolo M, et al. Among authors: puglisi s. Lancet Diabetes Endocrinol. 2023 Oct;11(10):720-730. doi: 10.1016/S2213-8587(23)00193-6. Epub 2023 Aug 21. Lancet Diabetes Endocrinol. 2023. PMID: 37619579 Free PMC article. Clinical Trial.
Prolonged Adrenal Insufficiency After the Discontinuation of Mitotane Therapy.
Muratori L, Pia A, Reimondo G, Pisano C, La Salvia A, Puglisi S, Scagliotti GV, Sperone P. Muratori L, et al. Among authors: puglisi s. Endocr Metab Immune Disord Drug Targets. 2020;20(3):485-487. doi: 10.2174/1871530319666190809144620. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 31544707
Is Follow-up of Adrenal Incidentalomas Always Mandatory?
Reimondo G, Muller A, Ingargiola E, Puglisi S, Terzolo M. Reimondo G, et al. Among authors: puglisi s. Endocrinol Metab (Seoul). 2020 Mar;35(1):26-35. doi: 10.3803/EnM.2020.35.1.26. Endocrinol Metab (Seoul). 2020. PMID: 32207261 Free PMC article. Review.
157 results